Phage Therapy to Prevent Nosocomial Bacterial Pneumonia in Patients with Severe COVID-19 in 2020 |Biomedgrid

The COVID-19 was reported to be a pandemic, according to the World Health Organization (WHO). Secondary bacterial pneumonia exacerbates respiratory problems and increases mortality in patients with COVID-19. Recently, 50% of the causes of death in these patients have been reported as nosocomial pneumonia in these cases. These bacteria have become multidrug-resistant. Phage production is a cost-benefit. Inhalation of phage cocktail with mesh nebulizer can be suitable to prevent secondary bacterial pulmonary infection in patients with severe COVID-19. To prevent secondary bacterial pneumonia and reduce mortality in patients with severe type COVID-19 and patients who are under a ventilator for a long time, the use of phage cocktail product by inhalation with mesh nebulizer device is recommended.